JP2016513640A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016513640A5 JP2016513640A5 JP2016500441A JP2016500441A JP2016513640A5 JP 2016513640 A5 JP2016513640 A5 JP 2016513640A5 JP 2016500441 A JP2016500441 A JP 2016500441A JP 2016500441 A JP2016500441 A JP 2016500441A JP 2016513640 A5 JP2016513640 A5 JP 2016513640A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- drug
- sirpα
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 12
- 239000003814 drug Substances 0.000 claims 10
- 102100004476 SIRPA Human genes 0.000 claims 8
- 101710024246 SIRPA Proteins 0.000 claims 8
- 229940079593 drugs Drugs 0.000 claims 8
- 102100013078 CD47 Human genes 0.000 claims 5
- 101700033237 CD47 Proteins 0.000 claims 5
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 102000004965 antibodies Human genes 0.000 claims 2
- 108090001123 antibodies Proteins 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 229920001184 polypeptide Polymers 0.000 claims 2
- 210000003743 Erythrocytes Anatomy 0.000 claims 1
- 102000001554 Hemoglobins Human genes 0.000 claims 1
- 108010054147 Hemoglobins Proteins 0.000 claims 1
- 210000003324 RBC Anatomy 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 238000005534 hematocrit Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 210000001995 reticulocyte Anatomy 0.000 claims 1
- 230000001225 therapeutic Effects 0.000 claims 1
Claims (12)
- ＣＤ４７に結合するか、または結合時にＳＩＲＰαを活性化しない条件でＳＩＲＰαに結合する抗体、可溶性のＳＩＲＰα結合ＣＤ４７フラグメント、可溶性のＣＤ４７結合ＳＩＲＰαフラグメント、及び高親和性のＳＩＲＰαポリペプチドから選択された抗ＣＤ４７薬の治療量を、対象の癌の治療の方法に使用される医薬組成物であって、
前記方法は、
（ａ）抗ＣＤ４７薬、第２の抗ＣＤ４７薬、及びそれらの組み合わせから選択された第１刺激剤を前記対象に、抗ＣＤ４７薬の治療上有効量の供与により前記対象を刺激する準治療量だけ供与し、治療上有効量は減少したヘマトクリットまたは減少したヘモグロビンによる赤血球の重大な減少をもたらさないこと、及び
（ｂ）抗ＣＤ４７薬の治療上有効量を前記対象に供与すること
を含み、
ステップ（ｂ）は、ステップ（ａ）の開始後、３日〜２１日の範囲で行われることを特徴とする医薬組成物。 - 前記方法は、ステップ（ａ）の後でかつステップ（ｂ）の前に、刺激剤の供与が効果的であるか否かを決定するステップを更に含み、該ステップは網状赤血球計数を行うことを含むことを特徴とする請求項１に記載の医薬組成物。
- 前記方法は、ステップ（ａ）の後でかつステップ（ｂ）の前に、第２刺激剤を前記対象に供与することを含むことを特徴とする請求項１または２に記載の医薬組成物。
- 前記ステップ（ｂ）は、治療上有効量が供与されるまで、段階的に増加する２倍またはそれ以上の濃度で抗ＣＤ４７薬を供与することを含むことを特徴とする請求項１〜３のいずれか１項に記載の医薬組成物。
- 前記ステップ（ｂ）は、２倍またはそれ以上の治療上有効量を供与することを含むことを特徴とする１〜４のいずれか１項に記載の医薬組成物。
- 前記対象はヒトであることを特徴とする請求項１〜５のいずれか１項に記載の医薬組成物。
- 前記対象は癌を有することを特徴とする請求項１〜６のいずれか１項に記載の医薬組成物。
- 前記抗ＣＤ４７薬は、ＣＤ４７に特異的に結合し、任意には抗体であることを特徴とする請求項１〜７のいずれか１項に記載の医薬組成物。
- 前記抗ＣＤ４７薬は、可溶性のＣＤ４７結合ＳＩＲＰαフラグメント及び高親和性のＳＩＲＰαポリペプチドから選択されたＳＩＲＰα薬であることを特徴とする請求項１〜７のいずれか１項に記載の医薬組成物。
- 前記抗ＣＤ４７薬または刺激剤の使用は、別の治療剤の使用と組み合わされることを特徴とする請求項１〜９のいずれか１項に記載の医薬組成物。
- 前記別の治療剤は、抗癌剤であることを特徴とする請求項１０に記載の医薬組成物。
- 請求項１〜１１のいずれか１項に記載の医薬組成物が使用される方法での刺激剤及び抗ＣＤ４７薬を含むことを特徴とするキット。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361800102P | 2013-03-15 | 2013-03-15 | |
| US61/800,102 | 2013-03-15 | ||
| PCT/US2014/018743 WO2014149477A1 (en) | 2013-03-15 | 2014-02-26 | Methods for achieving therapeutically effective doses of anti-cd47 agents |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018201216A Division JP6704974B2 (ja) | 2013-03-15 | 2018-10-25 | 抗ｃｄ４７薬の処理上有効量を達成するための方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016513640A JP2016513640A (ja) | 2016-05-16 |
| JP2016513640A5 true JP2016513640A5 (ja) | 2017-03-30 |
| JP6426693B2 JP6426693B2 (ja) | 2018-11-21 |
Family
ID=51580621
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016500441A Active JP6426693B2 (ja) | 2013-03-15 | 2014-02-26 | 抗ｃｄ４７薬の処理上有効量を達成するための方法 |
| JP2018201216A Active JP6704974B2 (ja) | 2013-03-15 | 2018-10-25 | 抗ｃｄ４７薬の処理上有効量を達成するための方法 |
| JP2020084674A Active JP7007422B2 (ja) | 2013-03-15 | 2020-05-13 | 抗ｃｄ４７薬の処理上有効量を達成するための方法 |
| JP2022001223A Active JP7246528B2 (ja) | 2013-03-15 | 2022-01-06 | 抗ｃｄ４７薬の処理上有効量を達成するための方法 |
| JP2023039709A Pending JP2023075275A (ja) | 2013-03-15 | 2023-03-14 | 抗ｃｄ４７薬の処理上有効量を達成するための方法 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018201216A Active JP6704974B2 (ja) | 2013-03-15 | 2018-10-25 | 抗ｃｄ４７薬の処理上有効量を達成するための方法 |
| JP2020084674A Active JP7007422B2 (ja) | 2013-03-15 | 2020-05-13 | 抗ｃｄ４７薬の処理上有効量を達成するための方法 |
| JP2022001223A Active JP7246528B2 (ja) | 2013-03-15 | 2022-01-06 | 抗ｃｄ４７薬の処理上有効量を達成するための方法 |
| JP2023039709A Pending JP2023075275A (ja) | 2013-03-15 | 2023-03-14 | 抗ｃｄ４７薬の処理上有効量を達成するための方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (8) | US9623079B2 (ja) |
| EP (3) | EP3792285A1 (ja) |
| JP (5) | JP6426693B2 (ja) |
| CN (3) | CN105189556A (ja) |
| AU (4) | AU2014238105B2 (ja) |
| CA (1) | CA2903773A1 (ja) |
| DK (1) | DK2970493T3 (ja) |
| ES (1) | ES2728066T3 (ja) |
| HK (1) | HK1219956A1 (ja) |
| IL (1) | IL241347B (ja) |
| PT (1) | PT2970493T (ja) |
| WO (1) | WO2014149477A1 (ja) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11072655B2 (en) * | 2008-01-15 | 2021-07-27 | The Board Of Trustees Of The Leland Stanford Junior University | Markers of acute myeloid leukemia stem cells |
| CA2965198C (en) | 2008-01-15 | 2021-02-16 | The Board Of Trustees Of The Leland Stanford Junior University | Markers of acute myeloid leukemia stem cells |
| KR20150093770A (ko) | 2012-12-12 | 2015-08-18 | 베스쿨럭스 인코포레이티드 | 치료적 ｃｄ４７ 항체 |
| US9221908B2 (en) | 2012-12-12 | 2015-12-29 | Vasculox, Inc. | Therapeutic CD47 antibodies |
| ES2728066T3 (es) * | 2013-03-15 | 2019-10-22 | Univ Leland Stanford Junior | Métodos para la obtención de dosis terapéuticamente eficaces de agentes anti-CD47 |
| EP3046627B1 (en) | 2013-09-18 | 2019-10-23 | The Board of Trustees of the Leland Stanford Junior University | Modulation of efferocytosis pathways for treatment of atherosclerotic disease |
| US10550187B2 (en) * | 2014-10-24 | 2020-02-04 | Incept, Llc | Extra luminal scaffold |
| RU2576614C1 (ru) * | 2015-01-19 | 2016-03-10 | ФЕДЕРАЛЬНОЕ ГОСУДАРСТВЕННОЕ БЮДЖЕТНОЕ УЧРЕЖДЕНИЕ "33 ЦЕНТРАЛЬНЫЙ НАУЧНО-ИССЛЕДОВАТЕЛЬСКИЙ ИСПЫТАТЕЛЬНЫЙ ИНСТИТУТ" Минобороны России | Способ поиска точки с дробным эффектом при определении эффективных доз веществ методом "одной точки" |
| PT3656443T (pt) * | 2015-01-21 | 2021-12-27 | Univ Leland Stanford Junior | Utilização de agonista trl e agente anti-cd47 para melhorar a fagocitose das células cancerígenas |
| EP3811972B1 (en) * | 2015-02-27 | 2023-01-11 | The Board of Trustees of the Leland Stanford Junior University | Combination therapy for treatment of atherosclerosis |
| SI3331902T1 (sl) | 2015-08-07 | 2021-09-30 | ALX Oncology Inc. | Konstrukti z domeno SIRP-alfa ali njegove različice |
| EP3349787A4 (en) | 2015-09-18 | 2019-03-27 | Arch Oncology, Inc. | THERAPEUTIC CD47 ANTIBODIES |
| GB2558131B (en) | 2015-09-21 | 2021-05-19 | Surface Oncology Inc | Anti-CD47 antibodies and methods of use |
| CN115569192A (zh) * | 2015-12-11 | 2023-01-06 | 小利兰·斯坦福大学托管委员会 | 以双重靶向cd47和egfr来治疗癌症 |
| US20170210803A1 (en) * | 2016-01-21 | 2017-07-27 | The Board Of Trustees Of The Leland Stanford Junior University | Treatment of cancer with combinations of immunoregulatory agents |
| EP3442578B1 (en) * | 2016-04-15 | 2022-02-09 | The Board of Trustees of the Leland Stanford Junior University | Methods for determining and achieving therapeutically effective doses of anti-cd47 agents in treatment of cancer |
| US9957576B2 (en) | 2016-04-21 | 2018-05-01 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for determining responsiveness to an anti-CD47 agent |
| CA3019841A1 (en) | 2016-04-29 | 2017-11-02 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for the prevention and treatment of surgical adhesions |
| US11618784B2 (en) | 2016-07-19 | 2023-04-04 | Teva Pharmaceuticals Australia Pty Ltd. | Anti-CD47 combination therapy |
| JOP20190009A1 (ar) | 2016-09-21 | 2019-01-27 | Alx Oncology Inc | أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها |
| WO2018075960A1 (en) | 2016-10-21 | 2018-04-26 | Tioma Therapeutics, Inc. | Therapeutic cd47 antibodies |
| WO2018081448A1 (en) | 2016-10-26 | 2018-05-03 | The Board Of Trustees Of The Leland Stanford Junior University | Modified immunoglobulin hinge regions to reduce hemagglutination |
| EP3534965A4 (en) | 2016-11-03 | 2020-06-24 | Trillium Therapeutics Inc. | IMPROVEMENTS IN CD47 BLOCKADERAPY THROUGH HDAC INHIBITORS |
| WO2018160739A1 (en) | 2017-02-28 | 2018-09-07 | The Board Of Trustees Of The Leland Stanford Junior University | Antifibrotic activity of cd47 blockade |
| US11078272B2 (en) | 2017-03-09 | 2021-08-03 | The Board Of Trustees Of The Leland Stanford Junior University | Treatment of pediatric brain tumors with targeting of CD47 pathway |
| KR20200019619A (ko) | 2017-06-21 | 2020-02-24 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | 혈액성 악성종양에 대한 cd47 표적 요법을 위한 투약 파라미터 |
| KR102646468B1 (ko) | 2017-08-02 | 2024-03-11 | 페인스 테라퓨틱스 인코포레이티드 | 항-cd47 항체 및 이의 용도 |
| US11802153B2 (en) | 2017-10-18 | 2023-10-31 | Forty Seven, Inc. | Anti-CD47 agent-based ovarian cancer therapy |
| WO2019079549A1 (en) | 2017-10-18 | 2019-04-25 | Forty Seven, Inc. | TREATMENT OF OVARY CANCER BY ANTI-CD47 AND ANTI-PD-L1 |
| JP7391845B2 (ja) | 2017-12-01 | 2023-12-05 | シージェン インコーポレイテッド | Ｃｄ４７抗体及びがんを治療するためのその使用 |
| JP7343528B2 (ja) * | 2018-02-12 | 2023-09-12 | フォーティ セブン， インコーポレイテッド | 抗ｃｄ４７抗体及び抗ｃｄ２０抗体を使用する抗がんレジメン |
| MX2020009774A (es) | 2018-03-21 | 2020-10-08 | Alx Oncology Inc | Anticuerpos contra proteína alfa reguladora de señal y métodos de uso. |
| US11591390B2 (en) | 2018-09-27 | 2023-02-28 | Celgene Corporation | SIRP-α binding proteins and methods of use thereof |
| BR112021005585A2 (pt) | 2018-09-27 | 2021-06-29 | Celgene Corporation | proteínas de ligação a sirpa e métodos de uso das mesmas |
| WO2020163692A1 (en) * | 2019-02-08 | 2020-08-13 | The Board Of Trustees Of The Leland Stanford Junior University | Treatment of cutaneous t cell lymphoma with targeting of cd47 pathway |
| WO2020242895A1 (en) * | 2019-05-24 | 2020-12-03 | Forty Seven, Inc. | Regimes for co-administration of immunotherapeutic agents against c-kit and cd47 |
| BR112021024003A2 (pt) | 2019-05-31 | 2022-04-19 | Alx Oncology Inc | Métodos de tratamento de câncer com fusão sirp alfa-fc em combinação com um inibidor de checkpoint imunológico |
| KR20220085796A (ko) | 2019-10-18 | 2022-06-22 | 포티 세븐, 인코포레이티드 | 골수이형성 증후군 및 급성 골수성 백혈병을 치료하기 위한 조합 치료 |
| CN115397853A (zh) | 2019-12-17 | 2022-11-25 | 辉瑞大药厂 | 对cd47、pd-l1具特异性的抗体及其用途 |
| WO2022130016A1 (en) | 2020-12-18 | 2022-06-23 | Instil Bio (Uk) Limited | Tumor infiltrating lymphocytes and anti-cd47 therapeutics |
| JP2024528081A (ja) * | 2021-07-28 | 2024-07-26 | アクティニウム ファーマシューティカルズ インコーポレイテッド | 癌の治療における放射免疫療法及びｃｄ４７遮断薬の組み合わせ |
| WO2023092089A1 (en) | 2021-11-19 | 2023-05-25 | Kist (Korea Institute Of Science And Technology) | Therapeutic compounds for red blood cell-mediated delivery of an active pharmaceutical ingredient to a target cell |
| AU2023205152A1 (en) * | 2022-01-10 | 2024-07-18 | Kiniksa Pharmaceuticals, Gmbh | Methods of treating or reducing risk of transplant rejection |
| WO2023154578A1 (en) | 2022-02-14 | 2023-08-17 | Sana Biotechnology, Inc. | Methods of treating patients exhibiting a prior failed therapy with hypoimmunogenic cells |
| WO2023183313A1 (en) | 2022-03-22 | 2023-09-28 | Sana Biotechnology, Inc. | Engineering cells with a transgene in b2m or ciita locus and associated compositions and methods |
| WO2024105180A1 (en) | 2022-11-16 | 2024-05-23 | Boehringer Ingelheim International Gmbh | Predictive efficacy biomarkers for anti-sirpa antibodies |
| WO2024124107A2 (en) | 2022-12-09 | 2024-06-13 | Pfizer Inc. | Cd47 blocking agent and anti-cd20 / anti-cd3 bispecific antibody combination therapy |
| WO2024121777A1 (en) | 2022-12-09 | 2024-06-13 | Pfizer Inc. | Cd47 blocking agent and anti-bcma / anti-cd3 bispecific antibody combination therapy |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020052309A1 (en) * | 1996-09-11 | 2002-05-02 | Athanasius A. Anagnostou | Method of treating endothelial injury |
| WO2002092784A2 (en) * | 2001-05-15 | 2002-11-21 | Emory University | POLYNUCLEOTIDES AND POLYPEPTIDES RELATING TO THE MODULATION OF SIRP α-CD47 |
| US20040213792A1 (en) | 2003-04-24 | 2004-10-28 | Clemmons David R. | Method for inhibiting cellular activation by insulin-like growth factor-1 |
| US20070113297A1 (en) | 2005-09-13 | 2007-05-17 | Yongguang Yang | Methods and compositions for inhibition of immune responses |
| US8377448B2 (en) | 2006-05-15 | 2013-02-19 | The Board Of Trustees Of The Leland Standford Junior University | CD47 related compositions and methods for treating immunological diseases and disorders |
| WO2009046541A1 (en) | 2007-10-11 | 2009-04-16 | University Health Network | MODULATION OF SIRPα - CD47 INTERACTION FOR INCREASING HUMAN HEMATOPOIETIC STEM CELL ENGRAFTMENT AND COMPOUNDS THEREFOR |
| CN101456911A (zh) | 2007-12-12 | 2009-06-17 | 江苏豪森药业股份有限公司 | 促红细胞生成素模拟肽衍生物及其可药用盐和其制备方法与用途 |
| CA3054220C (en) * | 2008-01-15 | 2022-10-11 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for manilpulating phagocytosis mediated by cd47 |
| CA2965198C (en) | 2008-01-15 | 2021-02-16 | The Board Of Trustees Of The Leland Stanford Junior University | Markers of acute myeloid leukemia stem cells |
| EP2111869A1 (en) | 2008-04-23 | 2009-10-28 | Stichting Sanquin Bloedvoorziening | Compositions and methods to enhance the immune system |
| SI2477648T1 (sl) * | 2009-09-15 | 2022-09-30 | The Board Of Trustees Of The Leland Stanford Junior University | Sinergijska terapija proti CD47 za krvne rake |
| WO2011041453A1 (en) * | 2009-09-29 | 2011-04-07 | The Board Of Trustees Of The Leland Stanford Junior University | Isolation and use of melanoma cancer stem cells |
| PL3789038T3 (pl) | 2010-05-14 | 2023-01-23 | The Board Of Trustees Of The Leland Stanford Junior University | Humanizowane i chimeryczne przeciwciała monoklonalne wobec cd47 |
| RS60606B1 (sr) | 2012-01-17 | 2020-08-31 | Univ Leland Stanford Junior | Reagensi sirp-alfa visokog affiniteta |
| EP2812443B1 (en) * | 2012-02-06 | 2019-05-29 | Inhibrx, Inc. | Cd47 antibodies and methods of use thereof |
| US20140140989A1 (en) * | 2012-02-06 | 2014-05-22 | Inhibrx Llc | Non-Platelet Depleting and Non-Red Blood Cell Depleting CD47 Antibodies and Methods of Use Thereof |
| EP2869845B1 (en) | 2012-07-06 | 2019-08-28 | Genmab B.V. | Dimeric protein with triple mutations |
| SG11201506132PA (en) * | 2013-02-06 | 2015-09-29 | Inhibrx Llc | Non-platelet depleting and non-red blood cell depleting cd47 antibodies and methods of use thereof |
| ES2728066T3 (es) * | 2013-03-15 | 2019-10-22 | Univ Leland Stanford Junior | Métodos para la obtención de dosis terapéuticamente eficaces de agentes anti-CD47 |
-
2014
- 2014-02-26 ES ES14768797T patent/ES2728066T3/es active Active
- 2014-02-26 EP EP20201319.9A patent/EP3792285A1/en active Pending
- 2014-02-26 EP EP19166334.3A patent/EP3536709A1/en active Pending
- 2014-02-26 CN CN201480015159.9A patent/CN105189556A/zh active Pending
- 2014-02-26 AU AU2014238105A patent/AU2014238105B2/en active Active
- 2014-02-26 DK DK14768797.4T patent/DK2970493T3/da active
- 2014-02-26 CN CN202210327266.1A patent/CN114917336A/zh active Pending
- 2014-02-26 CA CA2903773A patent/CA2903773A1/en active Pending
- 2014-02-26 CN CN202010960541.4A patent/CN112245586A/zh active Pending
- 2014-02-26 WO PCT/US2014/018743 patent/WO2014149477A1/en active Application Filing
- 2014-02-26 EP EP14768797.4A patent/EP2970493B1/en active Active
- 2014-02-26 US US14/769,069 patent/US9623079B2/en active Active
- 2014-02-26 PT PT14768797T patent/PT2970493T/pt unknown
- 2014-02-26 JP JP2016500441A patent/JP6426693B2/ja active Active
-
2015
- 2015-09-09 IL IL241347A patent/IL241347B/en active IP Right Grant
-
2016
- 2016-07-06 HK HK16107912.2A patent/HK1219956A1/zh unknown
-
2017
- 2017-02-02 US US15/423,325 patent/US10301387B2/en active Active
-
2018
- 2018-10-25 JP JP2018201216A patent/JP6704974B2/ja active Active
-
2019
- 2019-01-17 AU AU2019200294A patent/AU2019200294B2/en active Active
- 2019-04-04 US US16/375,238 patent/US11104731B2/en active Active
-
2020
- 2020-05-13 JP JP2020084674A patent/JP7007422B2/ja active Active
- 2020-11-17 AU AU2020270485A patent/AU2020270485B2/en active Active
- 2020-11-23 US US17/102,183 patent/US11136391B2/en active Active
-
2021
- 2021-08-12 US US17/401,046 patent/US20210380689A1/en active Pending
-
2022
- 2022-01-06 JP JP2022001223A patent/JP7246528B2/ja active Active
- 2022-05-02 US US17/734,949 patent/US11518806B2/en active Active
- 2022-05-02 US US17/734,904 patent/US11603404B2/en active Active
-
2023
- 2023-02-03 US US18/164,252 patent/US20230303688A1/en active Pending
- 2023-03-14 JP JP2023039709A patent/JP2023075275A/ja active Pending
-
2024
- 2024-08-20 AU AU2024210996A patent/AU2024210996A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016513640A5 (ja) | ||
| CY1122143T1 (el) | Φαρμακευτικοι συνδυασμοι που περιλαμβανουν εναν αναστολεα της b-raf, εναν αναστολεα του egfr και προαιρετικα εναν αναστολεα της ρι3κ-αλφα | |
| JP2018512391A5 (ja) | ||
| WO2015097621A3 (en) | Pharmaceutical combinations | |
| UA118453C2 (uk) | Спосіб лікування пухлин у пацієнта | |
| JP2012529021A5 (ja) | ||
| JP2016537417A5 (ja) | ||
| WO2014172376A3 (en) | Markers of tumor cell response to anti-cancer therapy | |
| JP2018508516A5 (ja) | ||
| EA201391017A1 (ru) | Способы и готовые лекарственные формы для лечения болезни альцгеймера | |
| JP2019515899A5 (ja) | ||
| JP2019532047A5 (ja) | ||
| RU2017132877A (ru) | Комбинация антагониста pd-1 и эрибулина для лечения рака | |
| RU2019109464A (ru) | Способы применения биспецифического антитела, которое распознает фактор свертывания ix и/или активированный фактор свертывания ix и фактор свертывания x и/или активированный фактор свертывания x | |
| GB2496794A (en) | Combination pharmaceutical composition and methods of treating and methods of treating functional diseases or conditions of gastrointestinal tract | |
| MX2023000796A (es) | Composicion farmaceutica, metodos para tratamiento y sus usos. | |
| RU2017134443A (ru) | Способ лечения с применением традипитанта | |
| WO2013071056A3 (en) | Combination drug therapy for the treatment of solid tumors | |
| JP2017533220A5 (ja) | ||
| WO2016059241A3 (en) | Lung cancer diagnostics and therapeutics with mir-660 | |
| JP2015511226A5 (ja) | ||
| JP2016519107A5 (ja) | ||
| EA202091974A1 (ru) | Связывающие bcma антитела и их применение | |
| EP4101472A4 (en) | ANTI-MEFLIN ANTIBODIES FOR USE IN THE TREATMENT OF CANCER IN A PERSON WITH CANCER AND PHARMACEUTICAL COMPOSITION CONTAINING SAID ANTIBODY | |
| JP2016531853A5 (ja) |